Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property
December 22, 2022 07:46 ET
|
Small Pharma Inc.
Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline...
First Patient Dosed in Small Pharma’s Drug Interaction Study
December 15, 2022 07:50 ET
|
Small Pharma Inc.
LONDON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma To Support University College London Research Project on Neuroplasticity
December 14, 2022 07:50 ET
|
Small Pharma Inc.
LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
December 08, 2022 17:00 ET
|
Small Pharma Inc.
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma to Participate in November Investor and Healthcare Conferences
November 11, 2022 07:50 ET
|
Small Pharma Inc.
LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
October 31, 2022 07:50 ET
|
Small Pharma Inc.
SPL028 is the Company’s injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and...
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
October 19, 2022 07:50 ET
|
Small Pharma Inc.
Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”),...
Small Pharma Reports Fiscal Second Quarter 2023 Highlights
October 14, 2022 17:05 ET
|
Small Pharma Inc.
Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion of 12-week follow up anticipated by year end...
Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder
September 19, 2022 07:30 ET
|
Small Pharma Inc.
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...
Small Pharma Enters Into Automatic Share Purchase Plan
September 13, 2022 17:00 ET
|
Small Pharma Inc.
LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted...